Revcovi is the only FDA-approved enzyme replacement therapy (ERT) indicated for the treatment of adenosine deaminase severe combined immune deficiency ADA-SCID pediatric and adult patients. Hear how Revcovi treatment, combined with the help of her family and healthcare team makes Ashley feel supported in her daily life.

2018年10月10日 · Revcovi 是由 Leadiant 生物科学公司开发的一种用于治疗 ADA-SCID 的聚乙醇化重组腺苷脱氨酶（rADA）。 Revcovi 是一款重组技术产品，它消除了从动物身上获取酶的需要，其通过补充必要的腺苷脱氨酶（ADA）水平而发挥作用。

REVCOVI is a drug used to treat adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. REVCOVI replaces the missing ADA enzyme in patients with...

2024年12月31日 · Revcovi is a man-made form of an enzyme called adenosine deaminase (ADA). ADA is important in the body for preventing the buildup of certain proteins harmful to the white blood cells that help your body fight infections. Revcovi is used to replace ADA in adults and children with adenosine deaminase severe combined immune deficiency (ADA-SCID).

2022年8月31日 · REVCOVI (elapegademase-lvlr) injection, 2.4 mg/1.5 mL (1.6 mg/mL), is a sterile, preservative free, clear, colorless solution for intramuscular use available as one single-dose vial per carton ...

Revcovi (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. You are encouraged to report negative side effects of prescription drugs to the FDA.

Revcovi® (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. IMPORTANT SAFETY INFORMATION

2024年8月26日 · REVCOVI is a recombinant adenosine deaminase indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. (1) Patients transitioning from Adagen to REVCOVI: The starting dose of REVCOVI is 0.2 mg/kg weekly, intramuscularly.

Revcovi is the only FDA-approved enzyme replacement therapy (ERT) indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) pediatric and adult patients. 1 Revcovi is the product of recombinant technology. It is a PEGylated recombinant adnosine deaminase (rADA) enzyme. 1

Revcovi ® (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. Please see the Full Prescribing Information. Learn more about Revcovi dosing and administration.